Navigation Links
Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
Date:12/11/2007

become infected with HBV this year.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that adverse events could cause the cessation of the Phase 3 registration studies and/or our development of clevudine, the risk that adverse events could cause the cessation of the Phase 1 combination study and/or our development of R7128, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commi
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... HARRISBURG, Pa. , Aug. 31, 2015 ... been reversed statewide since Pennsylvania ... the life-saving drug kits, naloxone. Heroin and ... in Pennsylvania , killing more individuals ... 2013, approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... DIEGO , Aug. 31, 2015 Regen ... today development of a novel means of delivering ... acid, RGBP-248, to liver tumors utilizing a clinically ... development overcomes previous hurdles with gene silencing therapeutics ... be delivered throughout the whole body.  By utilizing ...
(Date:8/31/2015)... PRINCETON, N.J. , Aug. 31, 2015  /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today it has ... by the Data Review Committee (DRC) earlier this ... SGX942.  SGX942 is a first-in-class innate defense regulator ...
Breaking Medicine Technology:Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
... May 18, 2011 Oclaro, Inc. (NASDAQ: ... communications and laser solutions, today outlined its complete line ... of future products.  As a leading provider of diodes ... leverage its world-class manufacturing operations, technology expertise and packaging ...
... 18, 2011 Cempra Pharmaceuticals Inc. today announced that Prabhavathi ... two upcoming investor conferences in Paris.  Dr. Fernandes will present ... a.m. CET, May 24, at the Hilton Arc de Triomphe. ... at 3:00 p.m. CET, May 24, at the Paris ...
Cached Medicine Technology:Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 2Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 3Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris 2
(Date:8/31/2015)... ... September 01, 2015 , ... Neuropsychiatric ... injury with emphasis on transcranial near-infrared laser phototherapy ”. , As corresponding author ... has been largely untreatable - with mostly palliative treatments only - and now ...
(Date:8/31/2015)... ... ... Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center is celebrating ... surgical and non-surgical disorders of the leg, ankle and foot. He also specializes ... , Dr. Paul Kovatis completed his orthopedic leg, ankle and foot fellowship training at ...
(Date:8/31/2015)... ... August 31, 2015 , ... Diablo Publications (DP), ... it has officially launched a new website and company identity ( diablopublications.com) . ... more closely aligned with the company’s strategic vision for growth and expansion over ...
(Date:8/31/2015)... Cokato, MN (PRWEB) , ... August 31, 2015 , ... ... and new product introductions: The Terrace Outdoor Sauna. After months of extensive engineering and ... attractive sauna model built to withstand the elements and is offered at a very ...
(Date:8/31/2015)... ... 2015 , ... Wyoming Medical Center, an acute care hospital ... Documentation Improvement (CDI) and medical coding needs. Based on a proprietary Natural Language ... an enterprise-level coding solution that combines CDI, Coding, Quality and Compliance Auditing modules ...
Breaking Medicine News(10 mins):Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Say “Hello” to the Brand New Finnleo Terrace Outdoor Saunas 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4
... Are Ignoring the Fight Against Cancer, CLEVELAND, ... took the stage for a final debate before ... matters important to the,American public but fell short ... cancer is an issue identified by 62 percent ...
... Clinton Defends Healthcare Plan Built on Extending Customers and ... Revenue of Private Insurance ... Moore,participated in a press conference call today organized by ... from the movie SiCKO, including Reggie Cervantes, a,9/11 rescue ...
... Aflac Incorporated,(NYSE: AFL ) announced today that ... 29th Annual Institutional Investors Conference. President and Chief,Financial ... he is scheduled to make a presentation on ... Incorporated presentation, Mr. Cloninger will discuss the,company,s outlook ...
... of the worlds pre-eminent experts in urogynecology at Oregon Health ... the National Institutes of Health to study the extent of ... , The pelvic floor comprises the muscle group that ... injury, which is caused by damage to pelvic muscles or ...
... Citing a Center for,Medicare and Medicaid Services (CMS) ... 20 percent of national health care spending by,2017, ... statement,urging the House to take up legislation introduced ... (D-Md.) to safeguard Medicare:, "Looking at this ...
... -- Millions of cancer patients take drugs to boost ... anemic after chemotherapy. But a new study by Northwestern ... erythropoiesis-stimulating agents (ESAs), actually raise patients, risk of death, ... , A meta-analysis of 51 trials with 13,613 patients ...
Cached Medicine News:Health News:Democratic Candidates Miss Key Health Issue in Debate 2Health News:Michael Moore Defends 9/11 Rescue Workers and Criticizes Insurance Industry on California Nurses Association Press Call 2Health News:Aflac Incorporated to Present at the Raymond James 29th Annual Institutional Investors Conference 2Health News:NIH awards OHSU researcher $1.2 million to determine causes of, risk factors for pelvic floor injury 2Health News:Blunt Cites New CMS Report in Calling for Action on Safeguarding Medicare 2Health News:Drug for anemic cancer patients raises risk of death 2Health News:Drug for anemic cancer patients raises risk of death 3
The COBE 2991 Cell Processor provides reliable, automated cell processing, with the control you need to get reproducible results in your lab. This versatile machine offers users reliability and multi...
The Wallac Multipette is used with 5 mL or 2.5 mL Combitips....
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... lightweight and balanced for smooth, one-handed control. ... comfort, reducing fatigue in even the longest ... physician to easily steer the catheter through ... one finger. Reflexion's auto-lock technology keeps the ...
Medicine Products: